StockNews.AI
CVAC
StockNews.AI
131 days

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

1. CureVac completed enrollment for glioblastoma study, data pending in H2 2025. 2. FDA approved Phase 1 study for squamous non-small cell lung cancer, starting in H2 2025.

Earnings
+4.7%Current Return
VS
-2.6%S&P 500
$2.9804/10 07:35 AM EDTEvent Start
$3.1204/11 02:00 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

CureVac's advancements in clinical trials and FDA approvals suggest positive future revenue potential, similar to previous drug approvals boosting stock prices in biotech.

How important is it?

The article highlights significant milestones in CureVac's pipeline that can drive future growth and stock performance.

Why Long Term?

The anticipated data reports and new study initiations in H2 2025 may influence the stock over the next few years.

Related Companies

BNTXMRNANVAX
Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first data readout anticipated in H2 2025 Filed IND and CTA submissions for Phase 1 study with proprietary off-the-shelf program in squamous non-small cell lung cancer (sqNSCLC) Received FDA clearance to proceed with sqNSCLC Phase 1 study; expected to  start in H2 2025 Invoiced €10 million milestone payment following initiation of Phase 1 of the combined Phase 1/2 study of a seasonal influenza/COVID-19 combination vaccine; program fully licensed to GSK Received positive validity decision for patent EP 3 708 668 B1 in amended form from European Patent Office (EPO) in inter partes proceedings against BioNTech SE Jury trial in U.S. litigation postponed to September 8, 2025, by the District Court of the Eastern District of Virginia Cash and cash equivalents position of €481.7 million as of December 31, 2024; reaffirming expected cash runway into 2028 CureVac to host conference call and webcast today at 9 a.m. EST / 3 p.m.

Related News